Vertex Pharmaceuticals (VRTX): analysis and statistics
Return, volatility, Sharpe ratio and risk for Vertex Pharmaceuticals, an S&P 500 component in the Health Care sector. Data as of 2026-07-30.
| Last close price | $481.70 |
| Sector (GICS) | Health Care |
| Annualized return (3.0 yr) | +11.05% |
| Total return over period | +36.71% |
| Annualized volatility | 29.44% |
| Sharpe ratio | 0.25 |
| Sortino ratio | 0.34 |
| Max drawdown | -29.07% |
| CVaR 95% (avg. loss, worst 5% of days) | -4.10% |
| Correlation with the S&P 500 | 0.27 |
| Period range | $340.48 – $529.59 |
| Trading days analyzed | 752 |
Over the last 3.0 years, Vertex Pharmaceuticals (VRTX) has posted an annualized return of +11.05% with annual volatility of 29.44%, a Sharpe ratio of 0.25. Its worst stretch (max drawdown from a peak) was -29.07%. Its correlation with the S&P 500 is 0.27, which means it moves fairly independently of the index, useful for diversification.
These are historical, realized metrics, not projections: they describe how the stock behaved, not how it will behave going forward. To see how VRTX would fit inside an optimized portfolio alongside other S&P 500 stocks, try the optimizer.
Optimize a portfolio with VRTX →
Other Health Care stocks
What is the Sharpe ratio? · How to optimize an S&P 500 portfolio